Abstract
The increasing knowledge regarding breast cancer carcinogenesis has provided possible opportunities to prevent breast cancer. This paper reviews the issues related to breast cancer chemoprevention including the identification of high-risk groups, biomarkers and potential chemopreventive agents. Trials with tamoxifen have clearly shown that the risk of developing estrogen receptor (ER)-positive breast cancer can be reduced at the later stage of this malignancy. However, there was no beneficial effect on ER-negative cancers. The challenge is to find new agents, which achieve same or better efficacy but with fewer side effects. Raloxifene has similar efficacy to tamoxifen, but leads to more favorable histologic profiles of endometrial tumors and fewer gynecologic symptoms and thrombo-embolic events. Adjuvant trials for contralateral tumors suggest that aromatase inhibitors may be able to prevent up to 70-80% of ER-positive breast cancers. This is currently being investigated in two large prevention trials, the IBIS-II trial using anastrozole and the MAP.3 trial using exemestane. We therefore need to discover novel agents for ER-negative breast cancer.
Keywords: Breast cancer, chemoprevention, prevention trials, tamoxifen, aromatase inhibitors, SERMs
Current Enzyme Inhibition
Title: Breast Cancer Chemoprevention: Current Perspectives
Volume: 5 Issue: 4
Author(s): Takeru Oyama, Yumiko Yasui and Takuji Tanaka
Affiliation:
Keywords: Breast cancer, chemoprevention, prevention trials, tamoxifen, aromatase inhibitors, SERMs
Abstract: The increasing knowledge regarding breast cancer carcinogenesis has provided possible opportunities to prevent breast cancer. This paper reviews the issues related to breast cancer chemoprevention including the identification of high-risk groups, biomarkers and potential chemopreventive agents. Trials with tamoxifen have clearly shown that the risk of developing estrogen receptor (ER)-positive breast cancer can be reduced at the later stage of this malignancy. However, there was no beneficial effect on ER-negative cancers. The challenge is to find new agents, which achieve same or better efficacy but with fewer side effects. Raloxifene has similar efficacy to tamoxifen, but leads to more favorable histologic profiles of endometrial tumors and fewer gynecologic symptoms and thrombo-embolic events. Adjuvant trials for contralateral tumors suggest that aromatase inhibitors may be able to prevent up to 70-80% of ER-positive breast cancers. This is currently being investigated in two large prevention trials, the IBIS-II trial using anastrozole and the MAP.3 trial using exemestane. We therefore need to discover novel agents for ER-negative breast cancer.
Export Options
About this article
Cite this article as:
Oyama Takeru, Yasui Yumiko and Tanaka Takuji, Breast Cancer Chemoprevention: Current Perspectives, Current Enzyme Inhibition 2009; 5 (4) . https://dx.doi.org/10.2174/157340809789630271
DOI https://dx.doi.org/10.2174/157340809789630271 |
Print ISSN 1573-4080 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6662 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Withdrawal Notice: Role, Significance and Association of microRNA-10a/b in Physiology of Cancer
MicroRNA Overview of Cantharidin and its Analogues
Current Medicinal Chemistry Colon as Target for Drug Delivery
Current Drug Therapy Editorial [Hot Topic: ABC Transporters: Role in Modulation of Drug Pharmacokinetics and in Physiopathology and Therapeutic Perspectives (Guest Editor: Francoise Van Bambeke)]
Current Drug Targets Toxicological Profile of Therapeutic Nanodelivery Systems
Current Drug Metabolism Multifuntional Nanoparticles: Preparation and Applications in Biomedicine and in Non-Invasive Bioimaging
Recent Patents on Nanotechnology Vascular Endothelial Growth Factor: A New Paradigm for Targeting Various Diseases
Current Angiogenesis (Discontinued) Synthesis, Computational Study, and Evaluation of In Vitro Antimicrobial, Antibiofilm, and Anticancer Activities of New Sulfanyl Aminonaphthoquinone Derivatives
Letters in Drug Design & Discovery Evaluation of Anticancer Activities of Gallic Acid and Tartaric Acid Vectorized on Iron Oxide Nanoparticles
Drug Delivery Letters HDAC Inhibitors-New Generation of Target Specific Treatment
Mini-Reviews in Medicinal Chemistry Enzymes To Die For: Exploiting Nucleotide Metabolizing Enzymes for Cancer Gene Therapy
Current Gene Therapy The Paradox of Oestradiol-Induced Breast Cancer Cell Growth and Apoptosis
Current Signal Transduction Therapy Inflammation, Serotonin and Major Depression
Current Drug Targets Stimuli-Responsive Nanoparticles for siRNA Delivery
Current Pharmaceutical Design Sirtuin Modulators: Mechanisms and Potential Clinical Implications
Current Medicinal Chemistry Disruption of Circadian Rhythms and Sleep in Critical Illness: Potential Implications for Angiogenesis After Myocardial Infarction. A Review
Current Pharmaceutical Design The Redox Regulation of Thiol Dependent Signaling Pathways in Cancer
Current Pharmaceutical Design Xenobiotic Metabolising Enzymes: Impact on Pathologic Conditions, Drug Interactions and Drug Design
Current Topics in Medicinal Chemistry Formulations, Pharmacodynamic and Clinical Studies of Nanoparticles for Lung Cancer Therapy - An Overview
Current Drug Metabolism Cellular and Molecular Surrogate Markers to Monitor Targeted and Non- Targeted Antiangiogenic Drug Activity and Determine Optimal Biologic Dose
Current Cancer Drug Targets